Abstract

Background: Role of oral contraceptive pill (OCP) and ormeloxifene (ORM) in dysfunctional uterine bleeding (DUB) is still in an exploring level. Aim: The aim was to observe the improvement of the menstrual bleeding pattern in terms of the amount, regularity, and hemoglobin (Hb) status of the women. Setting: Study was conducted in the Department of Obstetrics and Gynecology of IPGMER and SSKM Hospital, Kolkata a tertiary care teaching hospital. Design: Prospective randomized study with patients having subjective complaints of menorrhagia. Materials and Methods: A total of 36 women was treated with ORM 60 mg and OCP containing 30 μg ethinyl estradiol and 150 μg desogestrel was given to 34 women. Pictorial blood loss assessment chart (PBAC) was applied to assess the amount of bleeding. Statistical Analysis Used: Data were compared using a t-test (paired and unpaired) and Mann-Whitney U-test for numerical variables and McNemar's Chi-square test for categorical variables. Results: The primary outcome showed a comparable PBAC score of ORM in first posttreatment cycle and significantly better in following two cycles (PBAC - postC1: 0.118, PBAC - postC2: 0.016, and PBAC - postC3: 0.04). Group receiving OCP was observed to have good cycle regularity in comparison to ORM (P = 0.006). Hb rise in both groups was almost similar, OCP group revealed an improvement in mean Hb concentration of 0.65 g%, whereas ORM showed a rise of 0.72 g%. Secondary outcomes were adverse reactions, satisfaction level, and poor responders in both groups. Conclusion: ORM is effective in treating DUB in almost in all aspects and can be considered as nonsteroidal option of therapy.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.